Cargando…

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents

BACKGROUND: Lemborexant has demonstrated statistically significant improvements in sleep onset and sleep maintenance compared with placebo and zolpidem tartrate extended release, measured both objectively using polysomnography and subjectively using sleep diaries, in the phase 3 clinical trial SUNRI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikeda, Shunya, Azuma, Mie Kasai, Fujimoto, Kenichi, Shibahara, Hidetoshi, Inoue, Sachie, Moline, Margaret, Ishii, Mika, Mishima, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647554/ https://www.ncbi.nlm.nih.gov/pubmed/35506334 http://dx.doi.org/10.1017/S0033291722000356

Ejemplares similares

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: A model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents – CORRIGENDUM
por: Ikeda, Shunya, et al.
Publicado: (2022)

Lemborexant for insomnia
Publicado: (2021)

Efficacy and safety of lemborexant in midlife women with insomnia disorder
por: Terauchi, Masakazu, et al.
Publicado: (2023)

PSUN201 Efficacy and Safety of Lemborexant in Diabetic Patients With Insomnia Disorder
por: Moline, Margaret, et al.
Publicado: (2022)

The effect of lemborexant for insomnia disorder
por: Suzuki, Hidenobu, et al.
Publicado: (2021)

Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder
por: Dash, Amitabh, et al.
Publicado: (2022)

Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial
por: Takaesu, Yoshikazu, et al.
Publicado: (2023)

P096 Subjective ratings of medication strength of lemborexant over 6 months in subjects with moderate or severe insomnia
por: Drake, C, et al.
Publicado: (2021)

Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study
por: Mayleben, David, et al.
Publicado: (2021)

Pilot Study of Lemborexant for Insomnia in Cancer Patients with Delirium
por: Terada, Tatsuto, et al.
Publicado: (2022)

P097 Incidence of abnormal dreams and nightmares with lemborexant in adults with insomnia: results from two Phase 3 studies
por: Roth, T, et al.
Publicado: (2021)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
por: Landry, Ishani, et al.
Publicado: (2020)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial
por: Rosenberg, Russell, et al.
Publicado: (2019)

Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
por: Kärppä, Mikko, et al.
Publicado: (2020)

Risk assessment of fall-related occupational accidents in the workplace
por: Tsukada, Tsukimi, et al.
Publicado: (2016)

Comparison of the effect of lemborexant and other insomnia treatments on driving performance: a systematic review and meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study
por: Landry, Ishani, et al.
Publicado: (2022)

The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
por: Moline, Margaret, et al.
Publicado: (2023)

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Effects of Lemborexant on the Pharmacokinetics of Oral Contraceptives: Results From a Phase 1 Drug‐Drug Interaction Study in Healthy Females
por: Landry, Ishani, et al.
Publicado: (2021)

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
por: Vermeeren, Annemiek, et al.
Publicado: (2018)

Can Lemborexant for Insomnia Prevent Delirium in High-Risk Patients with Pancreato-Biliary Disease after Endoscopic Procedures under Deep Sedation?
por: Ogura, Takeshi, et al.
Publicado: (2022)

Erratum to: On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
por: Vermeeren, Annemiek, et al.
Publicado: (2020)

C-ITS Relevant Critical Vehicle-to-Vehicle Accident Scenarios for Accident Analysis
por: Bauder, Maximilian, et al.
Publicado: (2022)

Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double‐blind, placebo‐controlled, crossover study
por: Cheng, Jocelyn Y., et al.
Publicado: (2020)

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
por: Khazaie, Habibolah, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults
por: Landry, Ishani, et al.
Publicado: (2020)

The burden of insomnia in Japan
por: Mishima, Kazuo, et al.
Publicado: (2015)

FLUID study: study protocol for an open-label, single-centre pilot study to investigate the efFect of Lemborexant on sleep management in Japanese sUbjects aged 50 years and older with Insomnia Disorder
por: Okada, Ippei, et al.
Publicado: (2021)

Evaluation of SAMP8 Mice as a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer’s Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant
por: Beuckmann, Carsten T., et al.
Publicado: (2021)

Sleep problems are related to commuting accidents rather than to workplace accidents
por: Vargas-Garrido, Héctor, et al.
Publicado: (2021)

Economic Burden of Alzheimer’s Disease Dementia in Japan
por: Ikeda, Shunya, et al.
Publicado: (2021)

Impact of the Severity of Alzheimer’s Disease on the Quality of Life, Activities of Daily Living, and Caregiving Costs for Institutionalized Patients on Anti-Alzheimer Medications in Japan
por: Ashizawa, Takumi, et al.
Publicado: (2021)

Association between discrimination in the workplace and insomnia symptoms
por: Ju, Suhwan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dle0hh39fp65548g6eb7lj2njm